Yi Tang, Wen-Yu Zhu, Si-Ling Peng, Shuai Huang, Qiu-Ni Zhao, Si-Yuan Tan, Zi-Hui Yin, Yan Zhang, Jian-Qiang Peng, Hong-Wei Pan
{"title":"人附睾蛋白4在急性心肌梗死中的预后价值。","authors":"Yi Tang, Wen-Yu Zhu, Si-Ling Peng, Shuai Huang, Qiu-Ni Zhao, Si-Yuan Tan, Zi-Hui Yin, Yan Zhang, Jian-Qiang Peng, Hong-Wei Pan","doi":"10.2147/IJGM.S470399","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the prognostic value of human epididymis protein 4 (HE4) in patients with acute myocardial infarction (AMI).</p><p><strong>Patients and methods: </strong>A total of 212 consecutive patients diagnosed with AMI in the Department of Cardiovascular Medicine of Hunan Provincial People's Hospital from June 2020 to May 2021 were enrolled. We determined plasma HE4 levels at baseline. The patients were followed up regularly and the occurrence of major adverse cardiac events (MACE) was recorded after discharge.</p><p><strong>Results: </strong>After a mean follow-up period of 242 (159-427) days, 67 patients had MACE. Multivariate Cox regression analysis showed that HE4 was an independent predictor of MACE in patients with AMI [HR = 1.004 (1.002-1.007), P = 0.002]. Kaplan-Meier survival curves showed that patients with HE4 levels > 532.9 pmol/L had higher MACE compared with patients with ≤ 532.9 pmol/L HE4 levels (HR=4.044, 95% CI 2.373-6.890, P <0.001). Receiver operating characteristic (ROC) curve analysis showed that the area under the curve (AUC) of HE4 for predicting MACE was 0.734 (95% CI: 0.669-0.792, P < 0.001).</p><p><strong>Conclusion: </strong>Human epididymis protein 4 (HE4) might be a novel biomarker for predicting the prognosis of patients with AMI.</p>","PeriodicalId":14131,"journal":{"name":"International Journal of General Medicine","volume":"17 ","pages":"6243-6251"},"PeriodicalIF":2.1000,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11653861/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prognostic Value of Human Epididymis Protein 4 in Acute Myocardial Infarction.\",\"authors\":\"Yi Tang, Wen-Yu Zhu, Si-Ling Peng, Shuai Huang, Qiu-Ni Zhao, Si-Yuan Tan, Zi-Hui Yin, Yan Zhang, Jian-Qiang Peng, Hong-Wei Pan\",\"doi\":\"10.2147/IJGM.S470399\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To investigate the prognostic value of human epididymis protein 4 (HE4) in patients with acute myocardial infarction (AMI).</p><p><strong>Patients and methods: </strong>A total of 212 consecutive patients diagnosed with AMI in the Department of Cardiovascular Medicine of Hunan Provincial People's Hospital from June 2020 to May 2021 were enrolled. We determined plasma HE4 levels at baseline. The patients were followed up regularly and the occurrence of major adverse cardiac events (MACE) was recorded after discharge.</p><p><strong>Results: </strong>After a mean follow-up period of 242 (159-427) days, 67 patients had MACE. Multivariate Cox regression analysis showed that HE4 was an independent predictor of MACE in patients with AMI [HR = 1.004 (1.002-1.007), P = 0.002]. Kaplan-Meier survival curves showed that patients with HE4 levels > 532.9 pmol/L had higher MACE compared with patients with ≤ 532.9 pmol/L HE4 levels (HR=4.044, 95% CI 2.373-6.890, P <0.001). Receiver operating characteristic (ROC) curve analysis showed that the area under the curve (AUC) of HE4 for predicting MACE was 0.734 (95% CI: 0.669-0.792, P < 0.001).</p><p><strong>Conclusion: </strong>Human epididymis protein 4 (HE4) might be a novel biomarker for predicting the prognosis of patients with AMI.</p>\",\"PeriodicalId\":14131,\"journal\":{\"name\":\"International Journal of General Medicine\",\"volume\":\"17 \",\"pages\":\"6243-6251\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-12-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11653861/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of General Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/IJGM.S470399\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of General Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IJGM.S470399","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
目的：探讨人附睾蛋白4 （HE4）在急性心肌梗死（AMI）患者中的预后价值。患者和方法：纳入2020年6月至2021年5月湖南省人民医院心血管内科连续诊断为AMI的患者212例。我们在基线时测定血浆HE4水平。定期随访，出院后记录主要心脏不良事件（MACE）发生情况。结果：平均随访242（159-427）天，67例患者出现MACE。多因素Cox回归分析显示，HE4是AMI患者MACE的独立预测因子[HR = 1.004 (1.002 ~ 1.007), P = 0.002]。Kaplan-Meier生存曲线显示HE4水平为> 532.9 pmol/L的患者MACE高于HE4水平≤532.9 pmol/L的患者（HR=4.044, 95% CI 2.373 ~ 6.890， P）。结论：人附睾蛋白4 （HE4）可能是预测AMI患者预后的一种新的生物标志物。
Prognostic Value of Human Epididymis Protein 4 in Acute Myocardial Infarction.
Purpose: To investigate the prognostic value of human epididymis protein 4 (HE4) in patients with acute myocardial infarction (AMI).
Patients and methods: A total of 212 consecutive patients diagnosed with AMI in the Department of Cardiovascular Medicine of Hunan Provincial People's Hospital from June 2020 to May 2021 were enrolled. We determined plasma HE4 levels at baseline. The patients were followed up regularly and the occurrence of major adverse cardiac events (MACE) was recorded after discharge.
Results: After a mean follow-up period of 242 (159-427) days, 67 patients had MACE. Multivariate Cox regression analysis showed that HE4 was an independent predictor of MACE in patients with AMI [HR = 1.004 (1.002-1.007), P = 0.002]. Kaplan-Meier survival curves showed that patients with HE4 levels > 532.9 pmol/L had higher MACE compared with patients with ≤ 532.9 pmol/L HE4 levels (HR=4.044, 95% CI 2.373-6.890, P <0.001). Receiver operating characteristic (ROC) curve analysis showed that the area under the curve (AUC) of HE4 for predicting MACE was 0.734 (95% CI: 0.669-0.792, P < 0.001).
Conclusion: Human epididymis protein 4 (HE4) might be a novel biomarker for predicting the prognosis of patients with AMI.
期刊介绍：
The International Journal of General Medicine is an international, peer-reviewed, open access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies across all disease areas.
A key focus of the journal is the elucidation of disease processes and management protocols resulting in improved outcomes for the patient. Patient perspectives such as satisfaction, quality of life, health literacy and communication and their role in developing new healthcare programs and optimizing clinical outcomes are major areas of interest for the journal.
As of 1st April 2019, the International Journal of General Medicine will no longer consider meta-analyses for publication.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
